Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCG | P05129 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.31 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19812759 | 0.72 | PRKCI (0.36) | — | |
| SCHEMBL17980277 | 0.71 | CYP3A4 (0.48) | — | |
| SCHEMBL19812792 | 0.69 | MEN1 (0.43) | — | |
| SCHEMBL21355924 | 0.67 | PTPN5 (0.34) | — | |
| SCHEMBL1569443 | 0.67 | CHEK1 (0.40) | — | |
| SCHEMBL3368244 | 0.67 | CA2 (0.33) | — | |
| SCHEMBL19812842 | 0.67 | KDM4E (0.45) | — | |
| SCHEMBL3660584 | 0.65 | HTR2C (0.46) | — | |
| SCHEMBL31393884 | 0.64 | PRKCG (0.31) | PRKCGPRKCAPRKCD | |
| SCHEMBL19906482 | 0.64 | MEN1 (0.35) | PRKCGPRKCAPRKCD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2026-02-05 | — | — | US | disclosed |
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-12-12 | — | — | US | disclosed |
| EP-4464317-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | Sumitomo Pharma America, Inc. (US) | 2024-11-20 | — | — | EP | disclosed |
| EP-3494119-B1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA INC (US) | 2024-09-04 | — | — | EP | disclosed |
| US-11958862-B2 | Compounds and compositions and uses thereof | SUMITOMO PHARMA AMERICA, INC. (US) | 2024-04-16 | — | — | US | disclosed |
| CN-116514761-A | Compounds, compositions and uses thereof | 赛诺维信制药公司 | 2023-08-01 | — | — | CN | disclosed |
| CN-116283877-A | Compounds, compositions and uses thereof | 赛诺维信制药公司 | 2023-06-23 | — | — | CN | disclosed |
| CN-110088107-B | Compounds, compositions and uses thereof | 赛诺维信制药公司 | 2023-04-14 | — | — | CN | disclosed |
| US-20220340588-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. (US) | 2022-10-27 | — | — | US | disclosed |
| US-10927124-B2 | Compounds and compositions and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-20190308990-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS INC. | 2019-10-10 | — | — | US | disclosed |
| EP-3494119-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | Sunovion Pharmaceuticals Inc. (US) | 2019-06-12 | — | — | EP | disclosed |
| US-10196403-B2 | Compounds and compositions and uses thereof | SUNOVION PHARMACEUTICALS INC. (US) | 2019-02-05 | — | — | US | disclosed |
| US-20180030064-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. | 2018-02-01 | — | — | US | disclosed |
| US-20180030064-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUMITOMO PHARMA AMERICA, INC. | 2018-02-01 | — | — | US | disclosed |
| WO-2018023072-A2 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | SUNOVION PHARMACEUTICALS, INC. (US) | 2018-02-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196403-B2 | Compounds and compositions and uses thereof | CHAT, ACHE, MAOB | PRKCG 3804/4885PRKCA 4442/4885PRKCD 4443/4885 |
| US-20240409550-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | PRKCG 3804/4885PRKCA 4442/4885PRKCD 4443/4885 |
| US-20260035381-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | ADH1C, HTR6, CNR1 | PRKCG 2400/4885PRKCA 3190/4885PRKCD 2455/4885 |
| US-10927124-B2 | Compounds and compositions and uses thereof | CHAT, ACHE, MAOB | PRKCG 3804/4885PRKCA 4442/4885PRKCD 4443/4885 |
| US-11958862-B2 | Compounds and compositions and uses thereof | CHAT, ACHE, MAOB | PRKCG 3804/4885PRKCA 4442/4885PRKCD 4443/4885 |
| US-20180030064-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | PRKCG 3804/4885PRKCA 4442/4885PRKCD 4443/4885 |
| US-20220340588-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | PRKCG 3804/4885PRKCA 4442/4885PRKCD 4443/4885 |
| US-20190308990-A1 | COMPOUNDS AND COMPOSITIONS AND USES THEREOF | CHAT, ACHE, MAOB | PRKCG 3804/4885PRKCA 4442/4885PRKCD 4443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.